BACKGROUND AND OBJECTIVE: The management of rare tumors is difficult because of limited information on natural history. Our objective was to describe a long-term comprehensive prospective database with the assumption that with careful attention to patient, predisposing tumor and treatment variables, valuable knowledge could be obtained that could guide management. METHODS: In July of 1982, we began a prospective database of all adult patients admitted to our institution for a surgical procedure for soft tissue sarcoma. Patients were included if they had primary, locally recurrent or metastatic disease undergoing a surgical procedure. RESULTS: Over 3 decades, we entered 10,000 patients into our prospective soft tissue sarcoma database. Data were entered on a weekly or biweekly schedule with full participation of a multidisciplinary team and a dedicated sarcoma pathologist. Extensive information is available from this database. In this article, we describe distribution by site, histopathology, sex, size, and grade. We utilize this information along with outcome data for local recurrence, distant recurrence, disease specific, and overall survival. The value of molecular diagnosis is illustrated. CONCLUSIONS: Continuous prospective long-term databases are important to obtain knowledge particularly for rare tumors. Such data can be a rich resource for the development of prognostic indicators including nomograms and can be analyzed by Bayesian Belief Networks. These long-term data linked to collection of tumor and germ-line tissue at the time of an initial procedure will remain a resource for future decades.
BACKGROUND AND OBJECTIVE: The management of rare tumors is difficult because of limited information on natural history. Our objective was to describe a long-term comprehensive prospective database with the assumption that with careful attention to patient, predisposing tumor and treatment variables, valuable knowledge could be obtained that could guide management. METHODS: In July of 1982, we began a prospective database of all adult patients admitted to our institution for a surgical procedure for soft tissue sarcoma. Patients were included if they had primary, locally recurrent or metastatic disease undergoing a surgical procedure. RESULTS: Over 3 decades, we entered 10,000 patients into our prospective soft tissue sarcoma database. Data were entered on a weekly or biweekly schedule with full participation of a multidisciplinary team and a dedicated sarcoma pathologist. Extensive information is available from this database. In this article, we describe distribution by site, histopathology, sex, size, and grade. We utilize this information along with outcome data for local recurrence, distant recurrence, disease specific, and overall survival. The value of molecular diagnosis is illustrated. CONCLUSIONS: Continuous prospective long-term databases are important to obtain knowledge particularly for rare tumors. Such data can be a rich resource for the development of prognostic indicators including nomograms and can be analyzed by Bayesian Belief Networks. These long-term data linked to collection of tumor and germ-line tissue at the time of an initial procedure will remain a resource for future decades.
Authors: Kimberly Moore Dalal; Michael W Kattan; Cristina R Antonescu; Murray F Brennan; Samuel Singer Journal: Ann Surg Date: 2006-09 Impact factor: 12.969
Authors: Fritz C Eilber; Murray F Brennan; Frederick R Eilber; Sarah M Dry; Samuel Singer; Michael W Kattan Journal: Cancer Date: 2004-11-15 Impact factor: 6.860
Authors: Luigi Mariani; Rosalba Miceli; Michael W Kattan; Murray F Brennan; Maurizio Colecchia; Marco Fiore; Paolo G Casali; Alessandro Gronchi Journal: Cancer Date: 2005-01-15 Impact factor: 6.860
Authors: Robert J Canter; Li-Xuan Qin; Robert G Maki; Murray F Brennan; Marc Ladanyi; Samuel Singer Journal: Clin Cancer Res Date: 2008-12-15 Impact factor: 12.531
Authors: Jason S Gold; Mithat Gönen; Antonio Gutiérrez; Javier Martín Broto; Xavier García-del-Muro; Thomas C Smyrk; Robert G Maki; Samuel Singer; Murray F Brennan; Cristina R Antonescu; John H Donohue; Ronald P DeMatteo Journal: Lancet Oncol Date: 2009-09-28 Impact factor: 41.316
Authors: Samuel Singer; Nicholas D Socci; Grazia Ambrosini; Elliot Sambol; Penelope Decarolis; Yuhsin Wu; Rachael O'Connor; Robert Maki; Agnes Viale; Chris Sander; Gary K Schwartz; Cristina R Antonescu Journal: Cancer Res Date: 2007-07-15 Impact factor: 12.701
Authors: Ronald P Dematteo; Karla V Ballman; Cristina R Antonescu; Robert G Maki; Peter W T Pisters; George D Demetri; Martin E Blackstein; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Shreyaskumar Patel; Martin D McCarter; Jonathan A Polikoff; Benjamin R Tan; Kouros Owzar Journal: Lancet Date: 2009-03-18 Impact factor: 79.321
Authors: Melissa D Mathias; Alexander J Chou; Paul Meyers; Neerav Shukla; Meera Hameed; Narasimhan Agaram; Lu Wang; Michael F Berger; Michael Walsh; Alex Kentsis Journal: J Pediatr Hematol Oncol Date: 2016-07 Impact factor: 1.289
Authors: Adam Kline; Pramod Kamalapathy; Katharine Bruce; Kevin Raskin; Joseph Schwab; Santiago Lozano-Calderón Journal: Ann Surg Oncol Date: 2021-05-12 Impact factor: 5.344
Authors: Emily Z Keung; Jen-Wei Tsai; Ali M Ali; Janice N Cormier; Andrew J Bishop; B Ashleigh Guadagnolo; Keila E Torres; Neeta Somaiah; Kelly K Hunt; Jennifer A Wargo; Alexander J Lazar; Wei-Lien Wang; Christina L Roland Journal: Oncoimmunology Date: 2017-10-31 Impact factor: 8.110
Authors: Adriana C Gamboa; Cecilia G Ethun; Jeffrey M Switchenko; Joseph Lipscomb; George A Poultsides; Valerie Grignol; J Harrison Howard; T Clark Gamblin; Kevin K Roggin; Konstantinos Votanopoulos; Ryan C Fields; Shishir K Maithel; Keith A Delman; Kenneth Cardona Journal: J Am Coll Surg Date: 2019-08-01 Impact factor: 6.113
Authors: David A J Wilson; Aaron Gazendam; Julia Visgauss; David Perrin; Anthony M Griffin; Peter W Chung; Charles N Catton; David Shultz; Peter C Ferguson; Jay S Wunder Journal: Ann Surg Oncol Date: 2020-03-09 Impact factor: 5.344